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Background

• 1 in 5 US adults live with chronic
pain.1
• Multiple studies have concluded Black
patients are less likely to be
prescribed an opioid due to provider
bias and racial myths.2-4

Jefferson TriNetX Network
3,339,613 Patients

• Clinicians should avoid prescribing
opioid pain medication and
benzodiazepines concurrently
(recommendation category: A).

Aims

• Elucidate correlations of racial
disparities in the prescription of opioids
for chronic noncancer pain (CNCP)
before and after the release of the
current CDC Guideline.
• Investigate correlations of racial
disparities in the co-prescription of
opioids and benzodiazepines in CNCP
patients before and after the release of
the current CDC Guideline.

Figure 2: Post-Guideline, a
smaller percentage of White
patients were prescribed an
opioid (63%) than not prescribed
an opioid (71%). Inversely, a
larger percentage of Black
patients were prescribed an
opioid (37%) than not prescribed
an opioid (29%).

Exclusion Criteria:
History of Substance Use Disorder*
Rx for buprenorphine or
naltrexone
Age under 18
Hispanic or Latino Ethnicity
Race other than White or Black**

Chronic Noncancer Pain
Diagnosis***
367,335 Patients

• Data from 2007-2012 revealed that

Black race was associated with greater
odds of opioid dose reduction, but
concurrent benzodiazepine
prescription was not.3
• The current CDC Guideline for
Prescribing Opioids for Chronic Pain
(2016)5 recommends:
• Nonpharmacologic and nonopioid
pharmacologic therapy are preferred
for chronic pain (recommendation
category: A).

Figure 1: Pre-Guideline, a larger
percentage of White patients
were prescribed an opioid (74%)
than not prescribed an opioid
(64%). Inversely, a smaller
percentage of Black patients
were prescribed an opioid (26%)
than not prescribed an opioid
(36%).
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Figure 3: Out of patients
prescribed an opioid the
percentage of White patients
decreased pre-(74%) to postguideline (63%). Inversely, the
percentage of Black patients
increased pre-(26%) to postguideline (37%).

Figure 4: Out of patients not
prescribed an opioid the
percentage of White patients
increased pre-(64%) to postguideline (71%). Inversely, the
percentage of Black patients
decreased pre-(36%) to postguideline (29%).

Statistical analysis was done within the
TriNetX system utilizing Baseline Comparison
Statistics which uses Z-test to generate pvalues for categorical variables. ***p<0.001
****p<0.0001
*History of Substance Use Disorder: ICD-10 codes
F10-F16, F18-19
**American Indian/ Alaska Native, Asian, Native
Hawaiian or Other Pacific Islander were the other
races within TriNetX database that were excluded
from this analysis
***Chronic Noncancer Pain (ICD-10 codes): Chronic
pain (G89.0, G89.21, G89.22, G89.28, G89.29,
G89.4), Fibromyalgia (M79.7), Osteoarthritis (M15M19), Spondylopathies (M45, M47, M48, M49),
Dorsopathies (M50-M54), Chronic Parametritis
(N73.1), Female Chronic Pelvic Peritonitis (N73.4)
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• These results suggest that the CDC
Guideline is correlated with a decrease
in both opioid prescription and opioid
prescription with a concurrent
benzodiazepine prescription for CNCP
in White patients.

• Inversely, the CDC Guideline is

correlated with an increase in both
opioid prescription and opioid
prescription with a concurrent
benzodiazepine prescription for CNCP
in Black patients.
• The CDC Guideline for Prescribing
Opioids for Chronic Pain (2016) has
been correlated with a reversal in the
racial differences in the prescription of
opioids for CNCP.
• These results suggest the CDC Guideline
for Prescribing Opioids for Chronic Pain
(2016) has been effective in White
CNCP patients, but ineffective in Black
CNCP patients.

• The current CDC Guideline does not

address the issue of patient race and
provider bias in its recommendations.
In future CDC Guidelines, addressing
racial differences and provider bias in
opioid prescriptions for chronic pain
may help address the racial
discrepancies in guideline adherence.
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